midostaurin

Back to Drugs List

Associated Genetic Biomarkers

Associated Diseases

Overview

Generic Name(s):

midostaurin

Trade Name(s):

Rydapt

NCI Definition [1]:

A synthetic indolocarbazole multikinase inhibitor with potential antiangiogenic and antineoplastic activities. Midostaurin inhibits protein kinase C alpha (PKCalpha), vascular endothelial growth factor receptor 2 (VEGFR2), c-kit, platelet-derived growth factor receptor (PDGFR) and FMS-like tyrosine kinase 3 (FLT3) tyrosine kinases, which may result in disruption of the cell cycle, inhibition of proliferation, apoptosis, and inhibition of angiogenesis in susceptible tumors.

Biomarker-Directed Therapies

Midostaurin can be used in the treatment of acute myeloid leukemia. FLT3, FLT3 Codon 835 Missense, and FLT3 Codon 836 Missense are the most frequent biomarker inclusion criteria for use of midostaurin [2].

Acute Myeloid Leukemia +

Disease is predicted to be sensitive to midostaurin: -

Biomarker Criteria:

Sample must match one or more of the following:

FLT3 ITD, FLT3 Codon 835 Missense, FLT3 Codon 836 Missense, FLT3 D835del, FLT3 I836del

Clinical Setting(s): Consolidation Therapy (FDA, NCCN), Treatment Induction (FDA, NCCN)

Note: FDA-approved, in combination with standard cytarabine and daunorubicin induction and cytarabine consolidation, for adults with newly diagnosed, FLT3-mutated AML.

Biomarker Criteria: Sample must match one or more of the following: FLT3 ITD, FLT3 Codon 835 Missense, FLT3 Codon 836 Missense, FLT3 D835del, FLT3 I836del	Clinical Setting(s): Consolidation Therapy (FDA, NCCN), Treatment Induction (FDA, NCCN)
	Note: FDA-approved, in combination with standard cytarabine and daunorubicin induction and cytarabine consolidation, for adults with newly diagnosed, FLT3-mutated AML.

Clinical Trials

View Clinical Trials for midostaurin

Midostaurin has been investigated in 18 clinical trials, of which 9 are open and 9 are closed. Of the trials investigating midostaurin, 3 are phase 1 (2 open), 3 are phase 1/phase 2 (2 open), 7 are phase 2 (2 open), 1 is phase 2/phase 3 (1 open), 3 are phase 3 (2 open), and 1 is no phase specified (0 open).

FLT3 ITD, FLT3 Codon 835 Missense, and FLT3 Codon 836 Missense are the most frequent biomarker inclusion criteria for midostaurin clinical trials.

Acute myeloid leukemia is the most common disease being investigated in midostaurin clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Midostaurin

Top Biomarker Inclusion Criteria for Closed Clinical Trials Investigating Midostaurin

This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating midostaurin and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:

pkc412, RYDAPT, 4'-n-benzoylstaurosporine, benzamide, n-(2,3,9,10,11,12-hexahydro-9-methoxy-8-methyl-1-oxo-8,12-epoxy-1h,8h-2,7b,12a-triazadibenzo(a,g)cyclonona(cde)trinden-10-yl)-n-methyl-, (8alpha,9beta,10beta,12alpha)-, cgp-41251, rydapt, cgp 41 251, cgp41251, n-benzoyl-staurosporine, pkc 412, benzoylstaurosporine, midostaurin, pkc-412, n-benzoylstaurosporine, cgp 41251, n-benzoyl-staurosporine, 4'-n-benzoyl staurosporine, n-benzoylstaurosporine

Drug Categories [2]:

Serine/threonine kinase inhibitors, Tyrosine kinase inhibitors

Drug Target(s) [2]:

FLT3, KDR, KIT, PDGFRA, PDGFRB, PRKCA, PRKCB, PRKCD, PRKCE, PRKCG

NCIT ID [1]:

C1872

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.

Drugs /